Improving the efficiency and safety of iron deficiency treatment using micellar microencapsulation of iron (SUNACTIVE® Fe)

To date, Russia continues to rank among countries with significant public health problems in terms of the prevalence of iron deficiency. The main strategy for the prevention of iron deficiency in reproductive age is the additional intake of dietary supplements. However, according to statistics, up to 40% of patients stop taking iron supplements early due to side effects, which dictates the search for new ways to improve adherence to treatment. To this end, two directions are considered: changing the dosing regimen and the use of iron compounds produced using modern technologies that provide increased safety without compromising bioavailability and effectiveness. Iron pyrophosphate is a trivalent compound with very good tolerability but low bioavailability due to the low water solubility. The special patented SUNACTIVE^® nanotechnology provies maximum micronization of iron pyrophosphate to 0.3 microns, followed by micellization as part of lipophilic nanoparticles, which are most similar in structure to chylomicrons. The absorption of such a highly micronized form of iron pyrophosphate is comparable to that of ferrous sulfate, which is a reference for assessing the bioavailability of various iron salts. Lipophilic micelles additionally protect iron from the acidic environment of the stomach and create a natural transport system that provides a direct route for Fe³⁺ transport through M cells. This route of absorption helps the rapid entry of iron through the enterocytes into the lymph and then into the liver for incorporation into ferritin and transferrin. Part of the micelles release iron under the action of digestive enzymes in the duodenum and the beginning of the small intestine. Ascorbic acid promotes the transition of Fe³⁺ to Fe²⁺, which provides an additional pathway for iron absorption through ion transport with the participation of the divalent metal transporter DMT-1. BADS Bonoferlat* is a combination of micronized iron pyrophosphate produced in Italy using the patented SunActive^® Fe micellar microencapsulation technology and L-ascorbic acid. One capsule of Bonoferlat contains 30 mg of iron and 110 mg of ascorbic acid, which provides an effective molar ratio between them for adequate restoration of valence from Fe³⁺ to Fe²⁺. The iron in Bonoferlat is well tolerated, does not cause side effects from the gastrointestinal tract and does not interact with dairy products, tea, coffee and other foods, so it can be taken at any convenient time without loss of effectiveness. In the context of the growing prevalence of iron deficiency states, it is advisable to use Bonoferlat in strategies for the prevention of iron deficiency with an increased need for iron, to compensate for iron deficiency that occur due to the insufficient intake of heme iron with food as a result of diets or dietary habits, in violation of iron absorption, as well as to compensate for the deficiency iron in the complex therapy of iron deficiency anemia and sideropenia of various etiologies.